MBX Biosciences Calls 2026 “Pivotal” With Phase 3 Plans, Obesity Program, and $460M Cash Runway [Yahoo! Finance]
MBX Biosciences, Inc. (MBX)
Company Research
Source: Yahoo! Finance
is expected this quarter, one-year phase II OLE data in Q2, and a planned global registrational phase III start in Q3 alongside commercialization planning. The proprietary PEP platform uses a programmable prodrug approach and fatty acylation to produce slow-rising, steady exposure that may enable less frequent dosing and better tolerability; MBX-4291, a once-monthly GLP-1/GIP candidate, targets a 12-week readout in Q4 2026 to support monthly dosing claims. MBX ended the year with $373M in cash and completed an $87M ATM sale for a pro forma $460M cash runway , which management says funds operations into 2029, including canvuparatide phase III and pre-commercial activities. Interested in MBX Biosciences, Inc.? Here are five stocks we like better. MBX Biosciences (NASDAQ:MBX) executives outlined key clinical and development milestones expected through 2026 during an Oppenheimer life sciences team event featuring CEO Kent Hawryluk and Chief Medical Officer Samer Ali. The company h
Show less
Read more
Impact Snapshot
Event Time:
MBX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
MBX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
MBX alerts
High impacting MBX Biosciences, Inc. news events
Weekly update
A roundup of the hottest topics
MBX
News
- MBX Biosciences (MBX) had its "buy" rating reaffirmed by TD Cowen.MarketBeat
- MBX Biosciences Reports Fourth Quarter and Full-Year 2025 Financial Results and Recent Corporate Highlights [Yahoo! Finance]Yahoo! Finance
- MBX Biosciences Reports Fourth Quarter and Full-Year 2025 Financial Results and Recent Corporate HighlightsGlobeNewswire
- MBX Biosciences Appoints Karen Basbaum as Chief Business Officer [Yahoo! Finance]Yahoo! Finance
- MBX Biosciences Appoints Karen Basbaum as Chief Business OfficerGlobeNewswire
MBX
Earnings
- 3/12/26 - Beat
MBX
Sec Filings
- 3/12/26 - Form S-3ASR
- 3/12/26 - Form S-8
- 3/12/26 - Form 10-K
- MBX's page on the SEC website